Shanghai-based Fosun Pharma has scheduled its 2025 annual general meeting for 16 June 2026 in Shanghai, asking shareholders to approve a broad slate of operational and financing authorisations.
Key operating data for 2025 • Revenue rose 1.45 % to RMB41.66 billion; innovative-drug sales jumped 29.59 % to RMB9.89 billion, representing 33.16 % of pharmaceutical revenue. • Overseas business delivered RMB12.98 billion, up 14.87 % and accounting for 31.15 % of total revenue. • Group R&D outlays reached RMB5.91 billion, 72.77 % of which was devoted to innovative drugs.
Principal AGM resolutions Dividend – A final cash dividend of RMB0.39 per share (before tax) is proposed, payable in RMB to A-shareholders and in HKD to H-shareholders.
Auditors – Re-appointment of Ernst & Young Hua Ming LLP (PRC) and Ernst & Young (international) with 2025 fees of RMB2.80 million, RMB0.65 million and RMB1.21 million respectively.
Financing and treasury • Entrusted loans/borrowings: new and rollover quota capped at RMB15.50 billion. • Additional credit lines: applications to banks and other institutions totalling up to RMB38.50 billion. • Interbank debt instruments: registration and issuance of up to RMB8 billion, tenor not exceeding ten years. • Disposal of listed securities: management may sell holdings up to 10 % of latest audited net assets.
Guarantees – Aggregate renewed and additional guarantees limited to RMB35 billion, of which RMB30 billion may be provided to subsidiaries with debt-to-asset ratios below 70 % and RMB5 billion to higher-leveraged units.
Share capital mandates • Issue mandate: Board may issue up to 20 % of existing A or H shares (including sale of treasury H shares) during the mandate period. • Repurchase mandates: Authority to buy back up to 10 % of each share class; H-share proceeds may be cancelled or held as treasury shares, while A-share buybacks will follow PRC rules for subsequent cancellation or transfer.
Governance items Shareholders will also vote on 2025 Board and performance reports, directors’ remuneration policies, the 2026 appraisal programme, and the reworked Remuneration Management System for directors and senior executives.
The share register for H-shareholders will close 11–16 June 2026 (both days inclusive) with 10 June 2026 as the last day for lodging transfers.